These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16135655)

  • 41. Weight gain due to long term antipsychotic treatment of persistent mental disorders.
    Tadger S; Melamed Y
    Psychiatr Danub; 2008 Mar; 20(1):37-41. PubMed ID: 18376329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weight change and atypical antipsychotic treatment in patients with schizophrenia.
    Jones B; Basson BR; Walker DJ; Crawford AM; Kinon BJ
    J Clin Psychiatry; 2001; 62 Suppl 2():41-4. PubMed ID: 11232752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antipsychotic-induced weight gain: a review of the literature.
    Allison DB; Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 7():22-31. PubMed ID: 11346192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
    Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effectiveness criterion: balancing efficacy against the risks of weight gain.
    Citrome L
    J Clin Psychiatry; 2007; 68 Suppl 12():12-7. PubMed ID: 17956151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Olanzapine metabolic side effects: a weight gain issue?
    Carulli L; Mazzi F; Rondinella S; Bertolotti M
    Intern Emerg Med; 2008 Sep; 3(3):237-40. PubMed ID: 18369533
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of olanzapine in anorexia nervosa.
    Menaster M
    J Clin Psychiatry; 2005 May; 66(5):654-5; author reply 655-6. PubMed ID: 15889956
    [No Abstract]   [Full Text] [Related]  

  • 48. Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine.
    Zugno AI; Barcelos M; Oliveira Ld; Canever L; Luca RD; Fraga DB; Matos MP; Rezin GT; Scaini G; Búrigo M; Streck EL; Quevedo J
    Braz J Psychiatry; 2012 Jun; 34(2):168-75. PubMed ID: 22729413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neuroleptic adverse effects with emphasis on weight gain].
    Hebebrand J
    Z Kinder Jugendpsychiatr Psychother; 2009 Jul; 37(4):321-4. PubMed ID: 20306798
    [No Abstract]   [Full Text] [Related]  

  • 50. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel antipsychotics: comparison of weight gain liabilities.
    Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
    J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complications from olanzapine in a mentally healthy patient.
    West JC; Brasington SJ
    Am J Psychiatry; 2005 Sep; 162(9):1756. PubMed ID: 16135645
    [No Abstract]   [Full Text] [Related]  

  • 53. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 54. The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.
    Jacobowitz W; Derbabian B; Saunders A
    J Psychosoc Nurs Ment Health Serv; 2014 Jul; 52(7):30-7. PubMed ID: 24766105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Considerations regarding the use of metformin with olanzapine.
    Alamiri B
    Am J Psychiatry; 2008 Sep; 165(9):1205-6; author reply 1207. PubMed ID: 18765498
    [No Abstract]   [Full Text] [Related]  

  • 56. Weight gain and antipsychotics.
    Mackin P
    J Clin Psychiatry; 2005 Jul; 66(7):950-1; author reply 951. PubMed ID: 16013917
    [No Abstract]   [Full Text] [Related]  

  • 57. Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain.
    Sharpe JK; Stedman TJ; Byrne NM; Hills AP
    J Clin Psychiatry; 2005 Jul; 66(7):951-2; author reply 952. PubMed ID: 16013918
    [No Abstract]   [Full Text] [Related]  

  • 58. An open trial of olanzapine in children and adolescents with Asperger Disorder.
    Milin R; Simeon JG; Batth S; Thatte S; Dare GJ; Walker S
    J Clin Psychopharmacol; 2006 Feb; 26(1):90-2. PubMed ID: 16415715
    [No Abstract]   [Full Text] [Related]  

  • 59. Factors associated with weight gain with olanzapine.
    Gaur N; Grover S
    World J Biol Psychiatry; 2010 Mar; 11(2):156-7. PubMed ID: 20128715
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.
    He M; Deng C; Huang XF
    CNS Drugs; 2013 Jun; 27(6):423-34. PubMed ID: 23640535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.